Frontiers Cancer, more than a “COVID-19 co-morbidity”

Frontiers Neutralizing monoclonal antibodies against SARS-CoV-2

Frontiers Cancer, more than a “COVID-19 co-morbidity”

Frontiers Evaluation of the effect of the COVID-19 pandemic on

Frontiers Neutralizing monoclonal antibodies against SARS-CoV-2

PDF) COVID-19–Induced Modifications in the Tumor Microenvironment

Frontiers Effect of Comorbid Diabetes on Clinical

PDF) Cancer, more than a “COVID-19 co-morbidity”

Box-4 Cancer-specific risk factors for severe COVID-19 mortality

Frontiers Cancer, more than a “COVID-19 co-morbidity”

Frontiers The Impact of SARS-CoV-2 on the Most Common

Box-4 Cancer-specific risk factors for severe COVID-19 mortality

Frontiers Neutralizing monoclonal antibodies against SARS-CoV-2

Frontiers Exploring the potential common denominator

FAST: a fast and scalable factor analysis for spatially aware

Age-adjusted associations between comorbidity and outcomes of